Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial

Journal:

Annals of the Rheumatic Diseases

Published:

2026-05-13

DOI:

10.1016/j.ard.2026.02.007

Affiliations:

9

Authors:

9

Go to article

Institutions	Authors	Share
Bristol-Myers Squibb, United States of America (USA)	4.000000	0.44
NYU Langone Health, United States of America (USA)	1.000000	0.11
University of Michigan (U-M), United States of America (USA)	1.000000	0.11
NIHR Leeds Biomedical Research Centre, United Kingdom (UK)	1.000000	0.11
Oklahoma Medical Research Foundation (OMRF), United States of America (USA)	0.500000	0.06
OU Health Sciences Center (OUHSC), United States of America (USA)	0.500000	0.06
Hospital for Special Surgery (HSS), United States of America (USA)	0.333333	0.04
Weill Cornell Medicine, United States of America (USA)	0.333333	0.04
New York-Presbyterian Hospital, United States of America (USA)	0.333333	0.04

Interested in Clinical Sciences?